Sensus Healthcare Stock (NASDAQ:SRTS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.82

52W Range

$2.66 - $5.92

50D Avg

$3.66

200D Avg

$3.85

Market Cap

$44.61M

Avg Vol (3M)

$60.73K

Beta

1.09

Div Yield

-

SRTS Company Profile


Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

54

IPO Date

Jul 26, 2016

Website

SRTS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product Revenue$1.72M$247.00K-
Service Revenue$3.46M$3.20M-
Service$2.54M$1.96M$2.80M
Product$19.76M$36.40M$20.35M

Fiscal year ends in Dec 25 | Currency in USD

SRTS Financial Summary


Dec 25Dec 24Dec 23
Revenue$27.48M$41.81M$24.41M
Operating Income$-10.31M$8.09M$-382.00K
Net Income$-7.72M$6.65M$485.00K
EBITDA$-9.92M$8.52M$79.00K
Basic EPS$-0.47$0.41$0.03
Diluted EPS$-0.47$0.41$0.03

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 07, 26 | 4:30 PM
Q4 25Feb 12, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM

Peer Comparison


TickerCompany
BDMDBaird Medical Investment Holdings Limited
IPSCCentury Therapeutics, Inc.
PETSPetMed Express, Inc.
MDCXMedicus Pharma Ltd. Common Stock
SNTISenti Biosciences, Inc.
ICCMIceCure Medical Ltd
TELATELA Bio, Inc.
CTSOCytosorbents Corporation
KPTIKaryopharm Therapeutics Inc.
MDAISpectral AI, Inc.